Boehringer Ingelheim May Face Enhanced Legal Risk From FTC’s Orange Book Crackdown

Published on Feb 23, 2024

The Federal Trade Commission’s efforts to police improper patent listings in the FDA’s Orange Book has created legal risk for asthma inhaler makers, particularly those who have faced challenges from generic companies looking to enter the market, according to experts.

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

© 2024 the Capitol Forum